What is the purpose of this trial?
The purpose of this study is to assess the safety of Tregs + IL-2 and survival of Tregs in patients with recent onset T1DM who receive infusions of autologous Tregs + IL-2.
Ages: 18 - 45 years
University of California, San Francisco
Start Date: 05/25/2017
End Date: 07/31/2021
Last Updated: 02/22/2018
Study HIC#: 1607018090